Brendan Eckelman, Ph.D. Executive Advisor

Dr. Eckelman is the co-founder and Chief Scientific Officer of Inhibrx (NASDAQ: INBX), a San Diego based biotech recently acquired by Sanofi. Since cofounding Inhibrx in 2010, he has served as the head of the research team, overseeing several key functional areas spanning discovery and protein engineering to therapeutic development. He has extensive experience with all stages of oncology drug development from discovery through clinical trials. Prior to co-founding Inhibrx, Dr. Eckelman was a Research Investigator in the biotherapeutics group at the Genomics Institute of the Novartis Research Foundation. He conducted his graduate research at the Sanford-Burnham-Prebys Medical Discovery Institute and received a Ph.D. in Molecular Pathology from the University of California, San Diego (UCSD), School of Medicine. Dr. Eckelman received his B.S. in Molecular Biology and his M.S. in Biology from UCSD.